EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Rohit Loomba iD, Mark L Hartman, Eric J Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Cynthia Behling, Oscar W Cummings, Yuanyuan Tang, Bram Brouwers, Deborah A Robins und 5 weitere

New England Journal of Medicine · 25.07.2024 · 391 (4) · 299-310

DOI: 10.1056/nejmoa2401943 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 25.07.2024. Verfasst von Rohit Loomba und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Metabolic Dysfunction-Associated Steatotic Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicin…. Hauptthemen laut MEDLINE: Fatty Liver, Glucagon-Like Peptide-2 Receptor, Liver Cirrhosis. Die Arbeit wurde bisher 1051-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverGlucagon-Like Peptide-2 ReceptorLiver CirrhosisAdultAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugDouble-Blind MethodGastric Inhibitory PolypeptideInjections, SubcutaneousLiverTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide-2 ReceptorTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • From the Metabolic Dysfunction-Associated Steatotic Liver Disease Research Center, Division of Gastroenterology and Hepatology, Department of Medicine, University of California at San Diego, La Jolla (R.L.), and Pacific…

ORCID-Profile: Rohit Loomba

Förderung

  • Eli Lilly and Company

Zitieren

APA

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., Sanyal, A. J., & SYNERGY-NASH Investigators (2024). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine, 391(4), 299-310. https://doi.org/10.1056/nejmoa2401943

Vancouver

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2024;391(4):299-310. doi:10.1056/nejmoa2401943

BibTeX
@article{Loomba2024,
  author = {Loomba, Rohit and Hartman, Mark L and Lawitz, Eric J and Vuppalanchi, Raj and Boursier, Jérôme and Bugianesi, Elisabetta and Yoneda, Masato and Behling, Cynthia and Cummings, Oscar W and Tang, Yuanyuan and Brouwers, Bram and Robins, Deborah A and Nikooie, Amir and Bunck, Mathijs C and Haupt, Axel and Sanyal, Arun J and SYNERGY-NASH Investigators, SYNERGY-NASH Investigators},
  title = {Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {4},
  pages = {299--310},
  doi = {10.1056/nejmoa2401943}
}
Kostenlos starten →